Since the role of BCAT1 overexpression in glioma development was reported in 2013 [40], BCAT1 has received increasing attention as a prognostic tumour marker and an attractive target for cancer therapy in many types of tumours [27]. The gene discussed is BCAT1; the disease is central nervous system cancer.